BioHarvest Secures $1.2M Stage 2 Fragrance Development Contract, Retains 20% Stake
BioHarvest Sciences has signed a $1.2 million Stage 2 CDMO contract to develop a rare fragrance on its Botanical Synthesis platform after Stage 1 completion in March 2026. Under the six- to nine-month deal, BioHarvest retains 20% ownership of compositions and will produce material for commercial trials by mid-2027.
1. Contract Details
BioHarvest’s CDMO division has secured a $1.2 million Stage 2 contract to develop a highly prized fragrance compound using its proprietary Botanical Synthesis platform, following successful Stage 1 cell bank creation in March 2026. The agreement is governed by an NDA that withholds partner identity and specific target compounds.
2. Financial Terms and Ownership
Under the Stage 2 contract, BioHarvest retains a 20% ownership interest in the developed compositions and will serve as the manufacturing entity, earning contract manufacturing revenues alongside future royalties as the cell bank advances toward commercialization.
3. Timeline and Production Capacity
Stage 2 work is expected to span six to nine months, culminating in sufficient fragrance raw material output for commercial trials. Production readiness is slated for the second half of 2027, coinciding with commissioning of a new manufacturing facility.
4. Market Opportunity and Strategic Impact
The developed scent is valued at tens of thousands of dollars per kilogram in luxury fragrance markets, where premium ingredients account for a $23 billion segment of the $58.9 billion global industry. This contract positions BioHarvest to attract additional fragrance partners and scale a royalty-driven growth model.